Transcenta Holding Limited 創勝集團醫藥有限公司 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 有關就解決截至2024年12月31日止年度的 年度報告內無法表示意見所採取措施及行動的最新進展 創勝集團醫藥有限公司（「本公司」，連同其附屬公司統稱為「本集團」）董事會 （「董事會」）謹此向股東及潛在投資者提供有關就解決其截至2024年12月31日止年 度的年度報告（「年報」）內所載的無法表示意見（「無法表示意見」）所採取措施及 行動的執行進度的最新進展。本公告所用但並無另行界定的詞彙應與年報中所賦 予該等詞彙的涵義相同。 自於2025年4月22日刊發年報、於2025年7月11日刊發最新進展公告、於2025年8 月27日刊發中期業績公告及於2025年10月22日刊發後續更新公告以來，本集團就 最初於年報內所載的九項關鍵措施持續取得切實進展，該等措施旨在增強其財務 狀況、提升流動性並解決無法表示意見。有關執行進度、狀況及預期成果的 ...

Core Insights - The strategic cooperation agreement between Huajian Medical and Transcenta Holding aims to explore the potential RWA tokenization of six core innovative drug pipeline assets valued at over $1.5 billion, representing cutting-edge research in the global oncology treatment field [1][2] - This collaboration marks a significant milestone in the integration of technology and finance, as it represents the first issuance of high-value innovative drug intellectual property assets in RWA form in the capital market [1][2] Summary by Sections Strategic Cooperation - Huajian Medical and its subsidiaries have entered into a strategic cooperation agreement with Transcenta Holding and its subsidiaries to explore RWA tokenization of innovative drug pipeline assets [1] - The six core assets involved are TST003, TST005, TST786, TST105, TST106, and TST013, which are integrated into Transcenta Oncology Inc. in the U.S. [1] RWA Tokenization Benefits - The RWA tokenization aims to lock in the research value of high-value pipelines, allowing issuers to efficiently activate top pipeline assets at various clinical stages without diluting equity [2] - It provides a new channel for global capital allocation, offering professional investors a transparent, compliant, and efficient opportunity to invest in cutting-edge innovative drug intellectual property assets [2] - The innovative financing model is expected to accelerate the development of advanced therapies, ultimately benefiting global patients and addressing urgent unmet medical needs [2] Future Growth and Collaboration - The collaboration is anticipated to generate significant synergies, injecting strong momentum into the sustainable business growth and financial performance of the group [2] - The group will work closely with Transcenta to ensure the successful implementation of the project to high standards [2]

Core Insights - The strategic cooperation agreement between Huajian Medical and Transcenta Holding aims to explore the potential tokenization of six innovative drug pipeline assets valued at over $1.5 billion, marking a significant milestone in the integration of technology and finance in the pharmaceutical sector [1][2] Group 1: Strategic Cooperation - Huajian Medical and its subsidiaries have entered into a strategic cooperation agreement with Transcenta Holding and its subsidiaries to collaborate on the potential RWA tokenization of innovative drug pipeline assets [1] - The six core innovative drug pipeline assets include TST003, TST005, TST786, TST105, TST106, and TST013, which are integrated into Transcenta Oncology Inc. (US) [1] Group 2: RWA Tokenization Benefits - The tokenization process aims to lock in the research value of high-value pipelines, allowing issuers to efficiently activate top pipeline assets at various clinical stages without diluting equity [2] - It provides a new channel for global capital allocation, offering professional investors a transparent and compliant opportunity to invest in cutting-edge innovative drug intellectual property assets [2] - The innovative financing model is expected to accelerate the development of advanced therapies, ultimately benefiting global patients and addressing urgent unmet medical needs [2] Group 3: Future Growth and Collaboration - The collaboration is anticipated to generate significant synergies, injecting strong momentum into the sustainable business growth and financial performance of the group [2] - The group will work closely with Transcenta to ensure the successful implementation of the project to high standards [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何 責 任。 IVD Medical Holding Limited 華檢醫療控股有限公司 （於開曼群島註冊成立之有限公 司） （股份代號：1931） 自願性公告 與 創 勝 集 團 醫 藥 有 限 公 司（06628.HK）簽 署 涉15億美元 創新藥管線資產RWA代幣化之戰略合作協議 本 公 告 乃 由 華 檢 醫 療 控 股 有 限 公 司（「本公司」或「華檢醫療」，連 同 其 附 屬 公 司 統 稱「本集團」）自 願 作 出，旨 在 向 股 東 及 潛 在 投 資 者 提 供 本 集 團 業 務 發 展 的 最 新 資 料。 一、合作概況與六大創新藥管線亮點 本 公 司 董 事 會（「董事會」）欣 然 宣 佈，本 公 司 及 本 公 司 附 屬 公 司ETHK Inc及 ETHK HOLDINGS LIMITED與創勝集團醫藥有限公司Transcenta ...